Combined quinacrine and chlorpromazine therapy in fatal familial insomnia

Clinical Neuropharmacology

Volumn 27, Issue 4, 2004, Pages 201-203

  Benito León, Julián ^a,b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b NONE   (Spain)

Author keywords

Chlorpromazine; Fatal familial insomnia; Prion disease; Quinacrine; Treatment

Indexed keywords

CHLORPROMAZINE; MEPACRINE; PRION PROTEIN;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CASE REPORT; CREUTZFELDT JAKOB DISEASE; DEATH; DISEASE COURSE; DRUG WITHDRAWAL; FATAL FAMILIAL INSOMNIA; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PRION DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER;

ADULT; CHLORPROMAZINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; INSOMNIA, FATAL FAMILIAL; MALE; MIDDLE AGED; QUINACRINE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 4344628471     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000134853.36429.0e     Document Type: Article

References (12)

1. Lugaresi E, Medori R, Montagna P, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986;315:997-1003.
2. Almer G, Hainfellner JA, Brucke T, et al. Fatal familial insomnia: a new Austrian family. Brain. 1999;122:5-16.
3. Tabernero C, Polo JM, Sevillano MD, et al. Fatal familial insomnia: clinical, neuropathological, and genetic description of a Spanish family. J Neurol Neurosurg Psychiatry. 2000;68:774-777.
4. Love R. Old drugs to treat new variant Creutzfeldt-Jakob disease. Lancet. 2001;358:563.
5. Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology. 2002;58:1720-1725.
6. Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A. 2001;98:9836-9841.
7. Goodman LS, Gilman A. eds. The Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology, and Therapeutics for Physicians and Medical Students. New York: Macmillan; 1970.
8. Hardman JG, Limbird LL, Molinoff PB, et al., eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996.
9. The UK Creutzfeldt-Jakob Disease Surveillance Unit. Potential treatments for Creutzfeldt-Jakob disease [online]. Available at: www.cjd.ed.ac.uk/TREAT. htm.
10. Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol. 2002;52:503-506.
11. Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol. 2003;77:8462-8469.
12. Furukawa H, Takahashi M, Nakajima M, et al. Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho. 2002;60:1649-1657.